Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

CPS-immunization

Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.

BIOLOGICAL

malaria challenge infection, P. falciparum NF135.C10

Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

BIOLOGICAL

malaria challenge infection, P. falciparum NF166.C8

Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.

BIOLOGICAL

malaria challenge infection, P. falciparum NF54

Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.

DRUG

atovaquone/proguanil

All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.

Trial Locations (1)

6525 GA

Radboud university medical center, Nijmegen

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Radboud University Medical Center

OTHER

NCT02098590 - Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection | Biotech Hunter | Biotech Hunter